Activation of Akt protects cancer cells from growth inhibition induced by PKM2 knockdown

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metabolism

Background:

• Pyruvate kinase M2 (PKM2) is a key glycolytic enzyme and a target for cancer therapy.
• However, many cancer cells exhibit resistance to PKM2 knockdown, with limited impact on survival and proliferation.
• The rewiring of cellular signaling pathways in these resistant cells remains largely unexplored.

Purpose of the Study:

• To investigate the effects of PKM2 knockdown on cellular signaling pathways in PKM2 knockdown-resistant cancer cells.
• To determine if rewired pathways are essential for the survival of these cells.
• To explore potential therapeutic strategies combining PKM2 inhibition with signaling pathway targeting.

Main Methods:

• PKM2 knockdown in cancer cell lines.
• Analysis of cellular signaling pathways, focusing on PI3K-Akt.
• Assessment of cell survival, proliferation, growth inhibition, and apoptosis.
• Inhibition of the PI3K-Akt signaling pathway.

Main Results:

• PKM2 knockdown leads to the activation of the Akt signaling pathway in resistant cancer cells.
• Akt activation is a consequence of glycolysis disruption induced by PKM2 knockdown.
• Inhibition of the PI3K-Akt pathway significantly reduces growth and induces apoptosis in PKM2 knockdown cells.

Conclusions:

• Akt pathway activation is crucial for the survival of cancer cells with PKM2 knockdown.
• Combination therapy of PKM2 knockdown with PI3K or Akt inhibitors demonstrates potential for enhanced tumor cell killing.
• This research opens new avenues for developing drugs targeting both cell metabolism and aberrant Akt signaling in cancer treatment.